全文获取类型
收费全文 | 15849篇 |
免费 | 1032篇 |
国内免费 | 64篇 |
专业分类
耳鼻咽喉 | 237篇 |
儿科学 | 379篇 |
妇产科学 | 279篇 |
基础医学 | 2292篇 |
口腔科学 | 275篇 |
临床医学 | 1474篇 |
内科学 | 3337篇 |
皮肤病学 | 327篇 |
神经病学 | 1593篇 |
特种医学 | 772篇 |
外国民族医学 | 1篇 |
外科学 | 2520篇 |
综合类 | 115篇 |
一般理论 | 4篇 |
预防医学 | 864篇 |
眼科学 | 260篇 |
药学 | 1085篇 |
1篇 | |
中国医学 | 13篇 |
肿瘤学 | 1117篇 |
出版年
2022年 | 96篇 |
2021年 | 169篇 |
2020年 | 146篇 |
2019年 | 201篇 |
2018年 | 223篇 |
2017年 | 208篇 |
2016年 | 255篇 |
2015年 | 280篇 |
2014年 | 373篇 |
2013年 | 537篇 |
2012年 | 744篇 |
2011年 | 808篇 |
2010年 | 473篇 |
2009年 | 485篇 |
2008年 | 767篇 |
2007年 | 859篇 |
2006年 | 854篇 |
2005年 | 864篇 |
2004年 | 865篇 |
2003年 | 802篇 |
2002年 | 704篇 |
2001年 | 455篇 |
2000年 | 391篇 |
1999年 | 377篇 |
1998年 | 190篇 |
1997年 | 165篇 |
1996年 | 122篇 |
1995年 | 123篇 |
1994年 | 104篇 |
1993年 | 114篇 |
1992年 | 245篇 |
1991年 | 236篇 |
1990年 | 219篇 |
1989年 | 270篇 |
1988年 | 218篇 |
1987年 | 201篇 |
1986年 | 204篇 |
1985年 | 216篇 |
1984年 | 147篇 |
1983年 | 163篇 |
1982年 | 106篇 |
1981年 | 104篇 |
1980年 | 103篇 |
1979年 | 170篇 |
1978年 | 118篇 |
1977年 | 97篇 |
1976年 | 102篇 |
1975年 | 92篇 |
1974年 | 103篇 |
1973年 | 95篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Mt D. Dbrssy Chockalingam Ramanathan Danesh Ashouri Vajari Yixin Tong Thomas Schlaepfer Volker A. Coenen 《The European journal of neuroscience》2021,53(1):89-113
Deep brain stimulation (DBS) in psychiatric illnesses has been clinically tested over the past 20 years. The clinical application of DBS to the superolateral branch of the medial forebrain bundle in treatment‐resistant depressed patients—one of several targets under investigation—has shown to be promising in a number of uncontrolled open label trials. However, there are remain numerous questions that need to be investigated to understand and optimize the clinical use of DBS in depression, including, for example, the relationship between the symptoms, the biological substrates/projections and the stimulation itself. In the context of precision and customized medicine, the current paper focuses on clinical and experimental research of medial forebrain bundle DBS in depression or in animal models of depression, demonstrating how clinical and scientific progress can work in tandem to test the therapeutic value and investigate the mechanisms of this experimental treatment. As one of the hypotheses is that depression engenders changes in the reward and motivational networks, the review looks at how stimulation of the medial forebrain bundle impacts the dopaminergic system. 相似文献
4.
5.
6.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
7.
8.
Hanna Lee Mary K. Tan Andrew T. Yan Paul Angaran Paul Dorian Claudia Bucci Jean C. Gregoire Alan D. Bell Martin S. Green Peter L. Gross Allan Skanes Charles R. Kerr L. Brent Mitchell Jafna L. Cox Vidal Essebag Brett Heilbron Krishnan Ramanathan Carl Fournier Shaun G. Goodman 《The Canadian journal of cardiology》2019,35(2):160-168
Background
Physicians treating nonvalvular atrial fibrillation (AF) assess stroke and bleeding risks when deciding on anticoagulation. The agreement between empirical and physician-estimated risks is unclear. Furthermore, the association between patient and physician sex and anticoagulation decision-making is uncertain.Methods
We pooled data from 2 national primary care physician chart audit databases of patients with AF (Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation and Coordinated National Network to Engage Physicians in the Care and Treatment of Patients with Atrial Fibrillation Chart Audit) with a combined 1035 physicians (133 female, 902 male) and 10,927 patients (4567 female and 6360 male).Results
Male physicians underestimated stroke risk in female patients and overestimated risk in male patients. Female physicians estimated stroke risk well in female patients but underestimated the risk in male patients. Risk of bleeding was underestimated in all. Despite differences in risk assessment by physician and patient sex, > 90% of patients received anticoagulation across all subgroups. There was modest agreement between physician estimated and calculated (ie, CHADS2 score) stroke risk: Kappa scores were 0.41 (0.35-0.47) for female physicians and 0.34 (0.32-0.36) for male physicians.Conclusions
Our study is the first to examine the association between patient and physician sex influences and stroke and bleeding risk estimation in AF. Although there were differences in agreement between physician estimated stroke risk and calculated CHADS2 scores, these differences were small and unlikely to affect clinical practice; further, despite any perceived differences in the accuracy of risk assessment by sex, most patients received anticoagulation. 相似文献9.
10.
Lucia Nogovà MD Volker Diehl MD Andreas Engert MD 《Current hematologic malignancy reports》2006,1(1):60-65
Lymphocyte-predominant Hodgkin’s lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin’s
lymphoma (cHL). Treatment of LPHL patients using standard Hodgkin’s lymphoma protocols leads to complete remission in more
than 95% of patients. Survival and freedom from treatment failure are substantially worse in advanced-stage patients than
for early-stage patients. Thus, patients in advanced stages and those in early stages with unfavorable risk factors should
be treated similar to those with cHL. In contrast, patients with early-stage LPHL without risk factors might be sufficiently
treated with reduced-intensity programs having less severe adverse effects. As a result, treatment of early LPHL is rather
heterogeneous, including radiotherapy using extended-fleld technique, involved-fleld radiotherapy (IF-RT), combined-modality
treatment, and, more recently, monoclonal antibodies. Watch-and-wait strategy plays an important role in pediatric oncology,
to avoid adverse effects associated with therapy. IF-RT seems to be emerging as a treatment of choice for patients with stage
IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment
of Cancer, have adopted IF-RT as the treatment of choice for these patients. 相似文献